The involvement of gut microbiota in the anti-tumor effect of carnosic acid via IL-17 suppression in colorectal cancer

Siyu Li; Hongxin Yang; Lanzhou Li; Wenqi Wang; Hor Yue Tan; Yidi Qu; Di Wang

doi:10.1016/j.cbi.2022.110080

The involvement of gut microbiota in the anti-tumor effect of carnosic acid via IL-17 suppression in colorectal cancer

Siyu Li, Hongxin Yang, Lanzhou Li, Wenqi Wang, Hor Yue Tan^*, Yidi Qu, Di Wang^*

^*Corresponding author for this work

Centre for Chinese Herbal Medicine Drug Development Limited

Research output: Contribution to journal › Journal article › peer-review

20 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a malignant tumor that threatens human health worldwide. Disturbance of the gut microbiota caused by various external factors is one of the leading causes. Carnosic acid (CA) is a phenolic diterpene compound, mainly isolated from rosemary plants, with anti-inflammatory and anti-tumor properties. In this study, we aimed to investigate the role of CA in CRC development and its underlying mechanisms in B6/JGpt-Apc^em1Cin(min)/Gpt (Apc^Min/+) mice based on the analysis of gut microbiota, serum metabolomics, and tumor proteomics. Enzyme-linked immunosorbent assay (ELISA) and Western blot were performed to confirm the changes in cytokine and protein levels related to inflammation after CA administration. CA regulated the abundance of the gut microbiota, which further caused changes in the production of DL-lactic acid. CA suppressed the inflammatory response by reducing the levels of IL-1β, −6, and −17A. Overall, CA showed anti-CRC properties via modulation of gut microbiota and serum metabolites through NF-κB/STAT3 signaling to inhibit IL-17 expression in Apc^Min/+ mice. These results provide experimental evidence for the future treatment of CRC with CA.

Original language	English
Article number	110080
Journal	Chemico-Biological Interactions
Volume	365
DOIs	https://doi.org/10.1016/j.cbi.2022.110080
Publication status	Published - 25 Sept 2022

User-Defined Keywords

Carnosic acid
Colorectal cancer
Gut microbiota
Inflammation
Proteomics
Serum metabolomics
Humans
Gastrointestinal Microbiome
Colorectal Neoplasms/drug therapy
Abietanes/pharmacology
Animals
Mice
Interleukin-17

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cbi.2022.110080

Cite this

@article{5cfa4bd73604492dbf1f7f80fe8469ab,

title = "The involvement of gut microbiota in the anti-tumor effect of carnosic acid via IL-17 suppression in colorectal cancer",

abstract = "Colorectal cancer (CRC) is a malignant tumor that threatens human health worldwide. Disturbance of the gut microbiota caused by various external factors is one of the leading causes. Carnosic acid (CA) is a phenolic diterpene compound, mainly isolated from rosemary plants, with anti-inflammatory and anti-tumor properties. In this study, we aimed to investigate the role of CA in CRC development and its underlying mechanisms in B6/JGpt-Apcem1Cin(min)/Gpt (ApcMin/+) mice based on the analysis of gut microbiota, serum metabolomics, and tumor proteomics. Enzyme-linked immunosorbent assay (ELISA) and Western blot were performed to confirm the changes in cytokine and protein levels related to inflammation after CA administration. CA regulated the abundance of the gut microbiota, which further caused changes in the production of DL-lactic acid. CA suppressed the inflammatory response by reducing the levels of IL-1β, −6, and −17A. Overall, CA showed anti-CRC properties via modulation of gut microbiota and serum metabolites through NF-κB/STAT3 signaling to inhibit IL-17 expression in ApcMin/+ mice. These results provide experimental evidence for the future treatment of CRC with CA.",

keywords = "Carnosic acid, Colorectal cancer, Gut microbiota, Inflammation, Proteomics, Serum metabolomics, Humans, Gastrointestinal Microbiome, Colorectal Neoplasms/drug therapy, Abietanes/pharmacology, Animals, Mice, Interleukin-17",

author = "Siyu Li and Hongxin Yang and Lanzhou Li and Wenqi Wang and Tan, {Hor Yue} and Yidi Qu and Di Wang",

note = "Funding Information: This research was funded by the Jilin Province Science and Technology Development Plan (Medicine and Health Special Project) ( 20200201122JC and 20200201030JC ), the Science and Technology Research Project of Jilin Provincial Education Department of China ( JJKH20211227KJ ), the Founding for Innovation from Development and Reform Commission of Jilin Province ( 2021c035-6 ), the Industrial Technology Research and Development Program of Jilin Province ( 2020C036-5 and 2021C035-6 ), and the Construction Project of Emergency Reserve of Traditional Chinese Medicine Prescriptions for Major Epidemic Prevention and Control of Jilin Province in China. Publisher Copyright: {\textcopyright} 2022 Elsevier B.V. Copyright {\textcopyright} 2022 Elsevier B.V. All rights reserved.",

year = "2022",

month = sep,

day = "25",

doi = "10.1016/j.cbi.2022.110080",

language = "English",

volume = "365",

journal = "Chemico-Biological Interactions",

issn = "0009-2797",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The involvement of gut microbiota in the anti-tumor effect of carnosic acid via IL-17 suppression in colorectal cancer

AU - Li, Siyu

AU - Yang, Hongxin

AU - Li, Lanzhou

AU - Wang, Wenqi

AU - Tan, Hor Yue

AU - Qu, Yidi

AU - Wang, Di

N1 - Funding Information: This research was funded by the Jilin Province Science and Technology Development Plan (Medicine and Health Special Project) ( 20200201122JC and 20200201030JC ), the Science and Technology Research Project of Jilin Provincial Education Department of China ( JJKH20211227KJ ), the Founding for Innovation from Development and Reform Commission of Jilin Province ( 2021c035-6 ), the Industrial Technology Research and Development Program of Jilin Province ( 2020C036-5 and 2021C035-6 ), and the Construction Project of Emergency Reserve of Traditional Chinese Medicine Prescriptions for Major Epidemic Prevention and Control of Jilin Province in China. Publisher Copyright: © 2022 Elsevier B.V. Copyright © 2022 Elsevier B.V. All rights reserved.

PY - 2022/9/25

Y1 - 2022/9/25

N2 - Colorectal cancer (CRC) is a malignant tumor that threatens human health worldwide. Disturbance of the gut microbiota caused by various external factors is one of the leading causes. Carnosic acid (CA) is a phenolic diterpene compound, mainly isolated from rosemary plants, with anti-inflammatory and anti-tumor properties. In this study, we aimed to investigate the role of CA in CRC development and its underlying mechanisms in B6/JGpt-Apcem1Cin(min)/Gpt (ApcMin/+) mice based on the analysis of gut microbiota, serum metabolomics, and tumor proteomics. Enzyme-linked immunosorbent assay (ELISA) and Western blot were performed to confirm the changes in cytokine and protein levels related to inflammation after CA administration. CA regulated the abundance of the gut microbiota, which further caused changes in the production of DL-lactic acid. CA suppressed the inflammatory response by reducing the levels of IL-1β, −6, and −17A. Overall, CA showed anti-CRC properties via modulation of gut microbiota and serum metabolites through NF-κB/STAT3 signaling to inhibit IL-17 expression in ApcMin/+ mice. These results provide experimental evidence for the future treatment of CRC with CA.

AB - Colorectal cancer (CRC) is a malignant tumor that threatens human health worldwide. Disturbance of the gut microbiota caused by various external factors is one of the leading causes. Carnosic acid (CA) is a phenolic diterpene compound, mainly isolated from rosemary plants, with anti-inflammatory and anti-tumor properties. In this study, we aimed to investigate the role of CA in CRC development and its underlying mechanisms in B6/JGpt-Apcem1Cin(min)/Gpt (ApcMin/+) mice based on the analysis of gut microbiota, serum metabolomics, and tumor proteomics. Enzyme-linked immunosorbent assay (ELISA) and Western blot were performed to confirm the changes in cytokine and protein levels related to inflammation after CA administration. CA regulated the abundance of the gut microbiota, which further caused changes in the production of DL-lactic acid. CA suppressed the inflammatory response by reducing the levels of IL-1β, −6, and −17A. Overall, CA showed anti-CRC properties via modulation of gut microbiota and serum metabolites through NF-κB/STAT3 signaling to inhibit IL-17 expression in ApcMin/+ mice. These results provide experimental evidence for the future treatment of CRC with CA.

KW - Carnosic acid

KW - Colorectal cancer

KW - Gut microbiota

KW - Inflammation

KW - Proteomics

KW - Serum metabolomics

KW - Humans

KW - Gastrointestinal Microbiome

KW - Colorectal Neoplasms/drug therapy

KW - Abietanes/pharmacology

KW - Animals

KW - Mice

KW - Interleukin-17

UR - http://www.scopus.com/inward/record.url?scp=85135512546&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2022.110080

DO - 10.1016/j.cbi.2022.110080

M3 - Journal article

C2 - 35926579

AN - SCOPUS:85135512546

SN - 0009-2797

VL - 365

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

M1 - 110080

ER -

The involvement of gut microbiota in the anti-tumor effect of carnosic acid via IL-17 suppression in colorectal cancer

Abstract

User-Defined Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this